Cronos Group Inc.
CRON Healthcare Drug Manufacturers Specialty & Generic
Cronos Group Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.6 million, up 24.6% from fiscal 2024. In the quarter to June 2026, revenue grew 58.4%, EPS grew 190.0%, free cash flow grew 2,279.2% and total debt fell 4.71%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow CRON
Cronos Group Inc. (CRON) EV/Sales
As of 16 October 2026, Cronos Group Inc. (CRON) trades at a EV/Sales of 2.3×. Over the past ten years it has ranged from −4.1× (March 2020) to 424× (March 2018); the current reading is higher than 47% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.2× | — |
| FY2024 | −0.7× | — |
| FY2023 | −0.6× | — |
| FY2022 | 0.8× | (87.30%) |
| FY2021 | 6.1× | (75.39%) |
| FY2020 | 24.8× | (32.98%) |
| FY2019 | 37.0× | (74.60%) |
| FY2018 | 146× | (55.24%) |
| FY2017 | 326× | 0.00% |
| FY2016 | 326× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.4× | 64.39% |
| Mar 2026 | 0.8× | (32.06%) |
| Dec 2025 | 1.2× | (33.62%) |
| Sep 2025 | 1.8× | — |
| 34 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PAHC Phibro Animal Health Corporation compare | 1.5× |
| ANIP ANI Pharmaceuticals, Inc. compare | 1.8× |
| AMPH Amphastar Pharmaceuticals, Inc. compare | 2.0× |
| COLL Collegium Pharmaceutical, Inc. compare | 2.1× |
| CRON Cronos Group Inc. | 2.3× |
| PCRX Pacira BioSciences, Inc. compare | 2.3× |
| HROW Harrow, Inc. compare | 4.5× |
| XERS Xeris Biopharma Holdings, Inc. compare | 5.7× |
| ETON Eton Pharmaceuticals, Inc. compare | 13.2× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)